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To the Editor: 
Long-term treatment with the second-generation tyrosine kinase inhibitors (2ndGTKIs) 
nilotinib and dasatinib may result in cardiovascular (CV) complications. Accumulating 
evidence suggests that the combination of a median age at the time of chronic myeloid 
leukemia (CML) diagnosis of greater than 60 years, when CV adverse events (AEs) are 
common, and the CV toxicity of 2ndGTKIs represents per se a potential predisposing factor, 
which requires preventive strategies and CV surveillance in patients with CML [1-3]. 
Previous studies have suggested the usefulness of the Systematic Coronary Risk Evaluation 
(SCORE) assessment at disease baseline, a 10-year risk estimation of fatal CV disease based 
on sex, age, smoking habits, systolic blood pressure, and total cholesterol levels, to identify 
patients who are at heightened risk of CV AEs during nilotinib treatment [4-5]. A 
preventive strategy with primary prophylaxis based on aspirin remains under discussion. We 
therefore analyzed a large real-life cohort of Italian patients with CML treated with a 
2ndGTKIs as first- or subsequent-line of treatment. The primary objective was to evaluate the 
incidence of CV AEs and the association with the SCORE assessment and other baseline 
risk factors. The secondary objectives were to evaluate the role of primary prophylaxis in 
preventing CV atherothrombotic events. 
We identified consecutive adult patients with CML who initiated nilotinib or dasatinib as 
first- or subsequent-line treatment, between January 2012 and December 2015 in 20 Italian 
centers. Patients were stratified into low-moderate (SCORE ≤5%) or high-very high 
(SCORE >5%) CV risk. Additional risk factors were the presence of diabetes, body mass 
index > 24.5 kg/m2, mild or severe renal insufficiency, and dyslipidemia. Patients were also 
evaluated for comorbidities and a positive anamnesis of CV diseases, including angina, 
myocardial infarction, stroke, heart failure, arterial hypertension, cardiomyopathy, heart 
arrhythmia, valvular heart disease, aortic aneurysms, ischemic cerebrovascular events, 
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peripheral artery disease, thromboembolic disease and venous thrombosis. The presence of 
antithrombotic prophylaxis before initiating CML treatment was also recorded. The 
probability of the cumulative incidence of CV and atherothrombotic AEs was estimated 
after initiating treatment with 2ndGTKIs. The cumulative incidence of deep molecular 
response (MR4) was evaluated from the initiation of 2ndGTKIs treatment. Multivariate 
analyses were performed using the Cox proportional hazards regression model.  
A total of 506 patients with CML were retrospectively recruited. The patients’ 
characteristics are shown in supplemental table 1. The mean age at diagnosis was 52 years 
(range 18-87) and 57% were men. Sokal score was intermediate-high in 55% of patients. 
The mean follow-up time since CML diagnosis was 5.4 years (range 0.2-23). Overall, 286 
patients were treated with nilotinib and 220 with dasatinib. 2ndGTKIs were administered as 
first-, second-, and third-line treatment in 61%, 32%, and 7% of cases, respectively. The 
reasons for switching treatments in 196 patients were inefficacy in 63.8%, intolerance in 
29.6%, and protocol requirements in 6.6%. The majority of patients (93%) were classified 
as at low-intermediate risk (SCORE ≤5%) and 7% as at high-very high risk (SCORE>5%). 
A positive history for CV diseases was noted in 181 (35.8%) patients. The 60-month CV 
AE cumulative incidence registered in the total cohort of patients was 21.7±2.8%. Patients 
treated with nilotinib and dasatinib showed CV AE incidence of 24.7±3.9% and 16.4±3.7%, 
respectively (p=0.25; NS) (Supplemental figure 1). Patients treated with 2ndGTKIs 
administered as first- or second-line of treatment and as subsequent-line treatment showed a 
CV AE incidence of 12.9±3.5% and 22.9±4.4%, respectively (p=0.004). Patients with high-
very high SCORE showed significantly high incidence of CV AEs (46.6±16.6% vs. 
20±2.8%; p<0.001). 
The mean time between the initiation of 2ndGTKI treatment and the occurrence of  CV AEs 
was 35.5 (range 1-69) months. Overall, 68 CV AEs were registered, with 2 event-related 
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deaths; 40% of CV AEs were graded as 3/4 of common toxicity criteria. Supplemental table 
2 reports the CV AEs and their management in the real-life. We did not find any association 
between TKI dose and CV AE incidence. The frequency of peripheral arterial disease 
(PAOD or atheromasic carotid disease) was significantly high in patients undergoing 
nilotinib treatment. Two patients died due to myocardial infarction during treatment. 
Overall, in 44% of cases 2ndGTKI treatment did not require dose modification; 16% of 
patients reduced the dose and 40% of them discontinued the treatment. The majority of 
patients required additional diagnostic tests as ECG/cardiac ultrasound, peripheral vascular 
Doppler or cardiac angio-MR/CT; 7 patients underwent coronarography procedure and 13 
patients required invasive procedures as percutaneous transluminal angioplasty or 
application of coronary stents. 
The 5-year cumulative incidence of MR4 following 2ndGTKIs treatment was 69.9±2.6% and 
it was not significantly influenced by CV AE occurrence. 
Multivariate analysis showed that a positive history of CV diseases (p=0.002; hazart ratio 
(HR)=2.3, 95% confidence interval (C.I.)=1.3-3.8) and treatment with 2ndGTKIs 
administered as second-line or beyond (p=0.002; HR 2.3, 95% C.I.=1.3-3.5) was 
significantly associated with a high incidence of CV AEs (Supplemental table 3). We 
stratified patients using a simple score based on positive anamnesis for CV disease and a 
treatment with 2ndGTKIs administered as second-line or beyond. Patients with none or one 
factor were considered to be at standard risk; patients with both factors were considered to 
be at high-risk of CV AEs. The CV AE incidence was significantly higher in patients with a 
CML-CV high-risk score, with both risk factors, compared with that in patients with none or 
one factor (45.9±8.2% vs 16.3±4.4% and 18.7±3.9%, p<0.001) (Figure 1).  
Atherothrombotic diseases (myocardial infarction, angina, ischemic cerebrovascular events 
and peripheral vascular disease) were registered in 44 (8.7%) of patients. The 
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atherothrombotic AE incidence was 13.1±2.5%. Considering patients aged ≥60 years with 
high CML-CV risk score, the atherothrombotic AE incidence was significantly lower in 6 
patients who were treated with 100 mg/day of aspirin compared to that in 34 patients who 
did not undergo primary prophylaxis (0% vs. 58.2±18.9%; p=0.01) (Supplemental Figure 
2). Aspirine was administered for a median of 54 (range 21-64) and 46 (range 5-64) months 
to the group with and without CV AEs, respectively. Overall, we also found a trend towards 
a lower atherothrombotic AE incidence in 10 patients of varying ages with high CML-CV 
risk score who were treated with 100 mg/day of aspirin compared to that in the 59 patients 
who did not undergo primary prophylaxis (0% vs. 33.9± 9.5%; p=0.11).  
CV AEs represent off-target relevant complications of 2nd and 3rdG TKI treatment [6,7].  
Our study showed that a positive history for CV diseases and treatment with 2ndGTKIs 
administered as second-line or beyond was significantly associated with a higher incidence 
of CV AEs. Indeed, patients with both risk factors showed a 5-year CV-AE incidence of 
45.9%, which was significantly higher compared to that in patients with no or only one risk 
factor. Therefore, we suggest that this simple score (CML-CV total risk=2) represents an 
easy-to-use and rapid tool to identify patients with an increased risk of developing CV AEs 
if treated with nilotinib or dasatinib. These patients could benefit from switching to another 
TKI with a lower CV risk profile (imatinib or bosutinib), avoiding sequential administration 
of 2ndGTKIs or combining rotation therapy between 1st and 2ndGTKIs. Treatment 
discontinuation could represent a goal in CV high-risk patients with a stable and durable 
MR4 who meet minimal criteria for discontinuing treatment.  
The role of aspirin is debatable and no conclusive data have been published thus far. In 
patients aged ≥60 years with a CML-CV high risk=2 treated with 100 mg/day of aspirin, 
however, we observed a significantly lower incidence of atherothrombotic AEs compared to 
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that in those without primary prophylaxis. Future prospective studies are needed to further 
corroborate our preliminary findings.  
In conclusion, our findings emphasize the need to personalize prevention strategies based on 
CV risk factors. Data on the efficacy of primary prophylaxis in patients with high-risk CV-
CML score are promising, but need to be confirmed in prospective randomized trials. 
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Figure legends 
 
Figure 1. Cardio-vascular adverse event incidence in 436 patients with standard risk (0 or 1 
risk factor considering age ≥60 years and treatment with 2ndGTKIs administered as second-
line or beyond) and 70 patients with high-risk CML- cardiovascular score (both risk factors 
were present). 
2ndGTKI, second-generation tyrosine kinase inhibitor; CML, chronic myeloid leukemia. 
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